Assessment and management of male androgen disorders: an update

作者：Chan Irene^*; Fui Mark Ng Tang; Zajac Jeffrey D; Grossmann Mathis

来源：Australian Family Physician, 2014, 43(5): 277-282.

• men's health
• endocrine system diseases
• obesity
• diabetes mellitus

Background Male hypogonadism, caused by intrinsic pathology of the hypothalamic-pituitary-testicular (HPT) axis, is an under-diagnosed condition not to be missed. By contrast, late onset hypogonadism (LOH), due to functional suppression of the HPT axis from age-related comorbidities, may be less common than previously believed.
Objective
This article outlines the aetiology, clinical features, investigation and management of male hypogonadism and discusses the more controversial area of LOH.
Discussion
Pathologically based hypogonadism is, after a thorough diagnostic work-up, treated with testosterone replacement therapy, unless fertility is desired. LOFT with modest reductions in testosterone levels should primarily be managed by attention to lifestyle measures, especially weight loss, and optimisation of comorbidities. Clear treatment goals should be identified, and efficacy and safety should be monitored according to published clinical practice guidelines.

• 出版日期2014-5